SEC Form F-4 filed by Voyager Acquisition Corp

ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY – September 30, 2025 -- VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), and Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs). The combination of both technology platforms aims to unlock novel targeted therapies for the treatment of autoimmune and chronic immune diseases AOCs combine the specificity of monoclonal anti

ZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG ("VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp.,  a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ:VACH, "Voyager" or the "SPAC")), announced today the filing of a registration statement on Form F-4 (the "Registration Statement"), which includes a preliminary proxy statement, with the U.S. Securities and Exchange Commission ("SEC") in regards to the proposed Business Combination Agreement announced April 23, 2025. "We are excited to share this pivotal milestone in VERAXA's journey toward becoming a publi

ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), announced today it will be attending the upcoming ASCO Annual Meeting and BIO International Convention. At the conferences, Christoph Antz, CEO, and additional members of the VERAXA leadership team will be meeting with potential partners and investors, showcasing the Company's novel Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform, and sharing the Company's growth plans as it prepares to list on the NASDAQ later this year. VERAXA is leveraging its proprietary BiTAC p